{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T18:06:58Z","timestamp":1794852418868,"version":"4.9.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-025-03887-y","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T14:34:24Z","timestamp":1752503664000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Intracavitary perfusion with bevacizumab plus cisplatin versus cisplatin alone for malignant pleural effusion in lung cancer patients: a meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"23","author":[{"given":"Xiao","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songjiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"issue":"1","key":"3887_CR1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12931-024-02684-7","volume":"25","author":"F Gonnelli","year":"2024","unstructured":"Gonnelli F, Hassan W, Bonifazi M, Pinelli V, Bedawi EO, Porcel JM, Rahman NM, Mei F. Malignant pleural effusion: current understanding and therapeutic approach. Respir Res. 2024;25(1):47. https:\/\/doi.org\/10.1186\/s12931-024-02684-7.","journal-title":"Respir Res"},{"key":"3887_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2022.106802","volume":"196","author":"SI Bashour","year":"2022","unstructured":"Bashour SI, Mankidy BJ, Lazarus DR. Update on the diagnosis and management of malignant pleural effusions. Respir Med. 2022;196: 106802. https:\/\/doi.org\/10.1016\/j.rmed.2022.106802.","journal-title":"Respir Med"},{"issue":"10","key":"3887_CR3","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/j.amjmed.2022.04.017","volume":"135","author":"S Gayen","year":"2022","unstructured":"Gayen S. Malignant Pleural Effusion: Presentation, Diagnosis, and Management. Am J Med. 2022;135(10):1188\u201392. https:\/\/doi.org\/10.1016\/j.amjmed.2022.04.017.","journal-title":"Am J Med"},{"issue":"3","key":"3887_CR4","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s41030-023-00228-w","volume":"9","author":"N Keidan","year":"2023","unstructured":"Keidan N, Aujayeb A. Small Cell Lung Cancer and Pleural Effusion: An Analysis from a District General Hospital. Pulm Ther. 2023;9(3):359\u201365. https:\/\/doi.org\/10.1007\/s41030-023-00228-w.","journal-title":"Pulm Ther"},{"issue":"6","key":"3887_CR5","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1111\/cts.13260","volume":"15","author":"Y Yang","year":"2022","unstructured":"Yang Y, Du J, Wang YS, Kang HY, Zhai K, Shi HZ. Prognostic impact of pleural effusion in patients with malignancy: A systematic review and meta-analysis. Clin Transl Sci. 2022;15(6):1340\u201354. https:\/\/doi.org\/10.1111\/cts.13260.","journal-title":"Clin Transl Sci"},{"key":"3887_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.961440","volume":"12","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Yu L, Wang L, Wu Y, Chen H, Wang Q, Wu Y. Current status of and progress in the treatment of malignant pleural effusion of lung cancer. Front Oncol. 2022;12: 961440. https:\/\/doi.org\/10.3389\/fonc.2022.961440.","journal-title":"Front Oncol"},{"key":"3887_CR7","doi-asserted-by":"publisher","unstructured":"Choi HY, Chang JE (2023) Targeted Therapy for Cancers: From Ongoing Clinical Trials to FDA-Approved Drugs. Int J Mol Sci 24 (17). https:\/\/doi.org\/10.3390\/ijms241713618","DOI":"10.3390\/ijms241713618"},{"issue":"11","key":"3887_CR8","first-page":"4879","volume":"12","author":"J Zhao","year":"2022","unstructured":"Zhao J, Liu B, Liu N, Zhang B, He X, Ma Q, Wang Y. The role of angiogenesis in malignant pleural effusion: from basic research to clinical application. Am J Cancer Res. 2022;12(11):4879\u201391.","journal-title":"Am J Cancer Res"},{"issue":"1","key":"3887_CR9","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1080\/07853890.2022.2071977","volume":"54","author":"Z Xiang","year":"2022","unstructured":"Xiang Z, Deng X, He W, Yang Q, Ni L, Dehghan Shasaltaneh M, Maghsoudloo M, Yang G, Wu J, Imani S, Wen Q. Treatment of malignant pleural effusion in non-small cell lung cancer with VEGF-directed therapy. Ann Med. 2022;54(1):1357\u201371. https:\/\/doi.org\/10.1080\/07853890.2022.2071977.","journal-title":"Ann Med"},{"issue":"2","key":"3887_CR10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1080\/17476348.2018.1417042","volume":"12","author":"RL Sabang","year":"2018","unstructured":"Sabang RL, Gandhiraj D, Fanucchi M, Epelbaum O. Role of bevacizumab in the management of the patient with malignant pleural effusion: more questions than answers. Expert Rev Respir Med. 2018;12(2):87\u201394. https:\/\/doi.org\/10.1080\/17476348.2018.1417042.","journal-title":"Expert Rev Respir Med"},{"issue":"6","key":"3887_CR11","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.3892\/or.2013.2349","volume":"29","author":"N Du","year":"2013","unstructured":"Du N, Li X, Li F, Zhao H, Fan Z, Ma J, Fu Y, Kang H. Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer-mediated malignant pleural effusion. Oncol Rep. 2013;29(6):2332\u201340. https:\/\/doi.org\/10.3892\/or.2013.2349.","journal-title":"Oncol Rep"},{"issue":"10","key":"3887_CR12","doi-asserted-by":"publisher","first-page":"10575","DOI":"10.21037\/apm-21-2623","volume":"10","author":"Z Zhou","year":"2021","unstructured":"Zhou Z, Li H, Hu D, Xie L. Clinical efficacy of bevacizumab combined with cisplatin in the treatment of malignant pleural effusion and ascites caused by lung cancer: a randomized trial. Ann Palliat Med. 2021;10(10):10575\u201383. https:\/\/doi.org\/10.21037\/apm-21-2623.","journal-title":"Ann Palliat Med"},{"issue":"34","key":"3887_CR13","first-page":"17","volume":"15","author":"P Chen","year":"2022","unstructured":"Chen P, Ai Y. Clinical efficacy of bevacizumab combined with thoracic perfusion chemotherapy in the treatment of non-small cell lung cancer with malignant pleural effusion. Chinese Journal of Clinical Rational Drug Use. 2022;15(34):17\u20131923.","journal-title":"Chinese Journal of Clinical Rational Drug Use"},{"key":"3887_CR14","unstructured":"Ruiqi Lu, Hailiang Xu, Lihuan Wang, Jianmin Song, Chang Guo. Clinical Study of Bevacizumab Injection Combined with Cisplatin in the Treatment of Lung Cancer-Related Malignant Pleural Effusion. Chinese Science and Technology Periodical Database (Citation Edition): Medicine and Health. 2022(4):45\u201348."},{"issue":"2","key":"3887_CR15","first-page":"112","volume":"4","author":"J Deng","year":"2017","unstructured":"Deng J, Qingqing Su, Zhang S, Chu X. Efficacy and safety of intrapleural combination therapy with bevacizumab and chemotherapeutic agents for lung cancer-mediated malignant pleural effusion: a meta-analysis. Chinese Journal of Thoracic Surgery. 2017;4(2):112\u20139.","journal-title":"Chinese Journal of Thoracic Surgery"},{"issue":"5","key":"3887_CR16","first-page":"394","volume":"56","author":"SA Sahn","year":"2001","unstructured":"Sahn SA. Management of malignant pleural effusions. Monaldi Arch Chest Dis. 2001;56(5):394\u20139.","journal-title":"Monaldi Arch Chest Dis"},{"key":"3887_CR17","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston MLT, Page MJ, Welch WV Cochrane Handbook for Systematic Reviews of Interventions version 6.2. Cochrane; (2021). Available online at: http:\/\/www.training.cochrane.org\/handbook (accessed February 2021)."},{"issue":"7","key":"3887_CR18","first-page":"648","volume":"44","author":"Qu Bo","year":"2015","unstructured":"Bo Qu, Jiang W, Zhou Z. Clinical Research of Intrapleural Combination Therapy with Bevacizumab and Cisplatin for Non-small Cell Lung Cancer Mediated Malignant Pleural Effusion. Journal of China Medical University. 2015;44(7):648\u201352.","journal-title":"Journal of China Medical University"},{"issue":"2","key":"3887_CR19","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s10856-016-5785-3","volume":"29","author":"T Chen","year":"2016","unstructured":"Chen T, Li L, Wang Y, Liping Yu. Clinical Study of Bevacizumab Combined with DDP by Pleural Perfusion in the Treatment of Malignant Pleural Effusion. Journal of Mathematical Medicine. 2016;29(2):172\u20133.","journal-title":"Journal of Mathematical Medicine"},{"issue":"11","key":"3887_CR20","first-page":"814","volume":"36","author":"B Huang","year":"2016","unstructured":"Huang B. Evaluation of curative effect of bevacizumab combined with cisplatin in treatment of non-small cell lung cancer with malignant pleural effusion. International Journal of Respiration. 2016;36(11):814\u20137.","journal-title":"International Journal of Respiration"},{"issue":"7","key":"3887_CR21","first-page":"698","volume":"44","author":"F Lin","year":"2016","unstructured":"Lin F, Weiping Su, Jin R. Clinical analysis of bevacizumab combined with cisplatin in treatment of malignant pleural effusion in patients with non-small cell lung cancer. Clinical Journal of Medical Officers. 2016;44(7):698\u2013700.","journal-title":"Clinical Journal of Medical Officers"},{"issue":"4","key":"3887_CR22","first-page":"672","volume":"26","author":"M Bai","year":"2017","unstructured":"Bai M. Effect analysis of bevacizumab combined with cisplatin in the treatment of malignant pleural effusion caused by non-small cell lung cancer. Henan Medical Research. 2017;26(4):672\u20133.","journal-title":"Henan Medical Research"},{"issue":"4","key":"3887_CR23","first-page":"377","volume":"19","author":"D Xue","year":"2017","unstructured":"Xue D, Zhao X. Study on Effect of Bevacizumab Combined with Cisplatin on Pleural Effusion of Non-small Cell Lung Cancer. Chinese Journal of Medicinal Guide. 2017;19(4):377\u20138.","journal-title":"Chinese Journal of Medicinal Guide"},{"issue":"15","key":"3887_CR24","first-page":"244","volume":"7","author":"X Zheng","year":"2017","unstructured":"Zheng X, Chen W, Qian S, Changming Wu, Fang Z. Efficacy Evaluation of Bevacizumab Combined with Cisplatin Intrathoracic Therapy for Malignant Pleural Effusion. Journal of Frontiers of Medicine. 2017;7(15):244\u20136.","journal-title":"Journal of Frontiers of Medicine"},{"issue":"6","key":"3887_CR25","first-page":"125","volume":"31","author":"X Liu","year":"2018","unstructured":"Liu X, Zhao C, Zhang L. The Effect of Bevacizumab Combined with Cisplatin in the Treatment of Malignant Pleural Effusion in Patients with Non-Small Cell Lung Cancer. Chinese Journal of Medical Device. 2018;31(6):125\u20136.","journal-title":"Chinese Journal of Medical Device"},{"issue":"17","key":"3887_CR26","first-page":"139","volume":"5","author":"X Cui","year":"2019","unstructured":"Cui X. Clinical Efficacy of Bevacizumab Combined with Cisplatin in the Treatment of Malignant Pleural Effusion of Lung Cancer. Smart Healthcare. 2019;5(17):139\u201340.","journal-title":"Smart Healthcare"},{"issue":"13","key":"3887_CR27","first-page":"114","volume":"4","author":"Y Shi","year":"2019","unstructured":"Shi Y. Effect and Safety of Bevacizumab Combined with Cisplatin Intrapleural Infusion in the Treatment of Malignant Pleural Effusion of Non-Small Cell Lung Cancer. Doctor. 2019;4(13):114\u20135.","journal-title":"Doctor"},{"issue":"19","key":"3887_CR28","first-page":"3281","volume":"25","author":"Wu Tian","year":"2019","unstructured":"Tian Wu. Bevacizumab combined with cisplatin in the treatment of malignant pleural effusion in patients with NSCLC. International Medicine & Health Guidance News. 2019;25(19):3281\u20134.","journal-title":"International Medicine & Health Guidance News"},{"issue":"3","key":"3887_CR29","first-page":"67","volume":"14","author":"Wu Xiaowen","year":"2019","unstructured":"Xiaowen Wu, Huang Y, Cai D. Analysis of the Clinical Efficacy of Intrathoracic Injection in the Treatment of Malignant Pleural Effusion in Patients with Lung Cancer. China Practical Medicine. 2019;14(3):67\u20138.","journal-title":"China Practical Medicine"},{"issue":"4","key":"3887_CR30","first-page":"117","volume":"40","author":"Na Zhang","year":"2019","unstructured":"Zhang Na, He W, Yang X, Li G, Cui Y, Jianghong Wu. Analysis of the Clinical Effects of Bevacizumab Combined with Cisplatin Intrapleural Infusion on the Treatment of Malignant Pleural Effusion of Lung Adenocarcinoma. Journal of Kunming Medical University. 2019;40(4):117\u201320.","journal-title":"Journal of Kunming Medical University"},{"issue":"31","key":"3887_CR31","first-page":"110","volume":"18","author":"Y Song","year":"2020","unstructured":"Song Y. Efficacy of Bevacizumab Combined with Cisplatin in the Treatment of Malignant Pleural Effusion in Non-small Cell Lung Cancer. Guide of China Medicine. 2020;18(31):110\u20131.","journal-title":"Guide of China Medicine"},{"issue":"5","key":"3887_CR32","first-page":"59","volume":"19","author":"M You","year":"2021","unstructured":"You M, Lv F, Wang S. Analysis of the Effectiveness of Bevacizumab Combined with Intrathoracic Chemotherapy in the Treatment of Non-Small Cell Lung Cancer with Malignant Pleural Effusion. Contemporary Medicine Forum. 2021;19(5):59\u201361.","journal-title":"Contemporary Medicine Forum"},{"key":"3887_CR33","unstructured":"Huanming Zhang. The Application Value of Bevacizumab Combined with Cisplatin in the Treatment of Malignant Pleural Effusion in Lung Cancer. Chinese Science and Technology Periodical Database (Full-Text Edition): Medicine and Health. 2021;(6):0029\u20130029, 31."},{"issue":"1","key":"3887_CR34","doi-asserted-by":"publisher","first-page":"20220575","DOI":"10.1515\/biol-2022-0575","volume":"18","author":"L Yang","year":"2023","unstructured":"Yang L, Wang Y. Malignant pleural effusion diagnosis and therapy. Open Life Sci. 2023;18(1):20220575. https:\/\/doi.org\/10.1515\/biol-2022-0575.","journal-title":"Open Life Sci"},{"issue":"17","key":"3887_CR35","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1097\/CM9.0000000000003231","volume":"137","author":"Z Guo","year":"2024","unstructured":"Guo Z, Jing X, Sun X, Sun S, Yang Y, Cao Y. Tumor angiogenesis and anti-angiogenic therapy. Chin Med J (Engl). 2024;137(17):2043\u201351. https:\/\/doi.org\/10.1097\/CM9.0000000000003231.","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"3887_CR36","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3892\/etm_00000001","volume":"1","author":"F Economidou","year":"2010","unstructured":"Economidou F, Margaritopoulos G, Antoniou KM, Siafakas NM. The angiogenetic pathway in malignant pleural effusions: Pathogenetic and therapeutic implications. Exp Ther Med. 2010;1(1):3\u20137. https:\/\/doi.org\/10.3892\/etm_00000001.","journal-title":"Exp Ther Med"},{"issue":"6","key":"3887_CR37","doi-asserted-by":"publisher","first-page":"8019","DOI":"10.3892\/mmr.2018.8922","volume":"17","author":"Y Chen","year":"2018","unstructured":"Chen Y, Mathy NW, Lu H. The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with non-small cell lung cancer (Review). Mol Med Rep. 2018;17(6):8019\u201330. https:\/\/doi.org\/10.3892\/mmr.2018.8922.","journal-title":"Mol Med Rep"},{"issue":"3","key":"3887_CR38","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s11912-013-0315-7","volume":"15","author":"M Bradshaw","year":"2013","unstructured":"Bradshaw M, Mansfield A, Peikert T. The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion. Curr Oncol Rep. 2013;15(3):207\u201316. https:\/\/doi.org\/10.1007\/s11912-013-0315-7.","journal-title":"Curr Oncol Rep"},{"issue":"9","key":"3887_CR39","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.21037\/tlcr-24-347","volume":"13","author":"K Hisakane","year":"2024","unstructured":"Hisakane K, Atsumi K, Seike M, Hirose T. Utility of atezolizumab plus bevacizumab, carboplatin, and paclitaxel combination for the treatment of advanced non-squamous non-small cell lung cancer patients with malignant pleural effusion. Transl Lung Cancer Res. 2024;13(9):2106\u201315. https:\/\/doi.org\/10.21037\/tlcr-24-347.","journal-title":"Transl Lung Cancer Res"},{"issue":"4","key":"3887_CR40","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1554969","volume":"8","author":"P Murthy","year":"2019","unstructured":"Murthy P, Ekeke CN, Russell KL, Butler SC, Wang Y, Luketich JD, Soloff AC, Dhupar R, Lotze MT. Making cold malignant pleural effusions hot: driving novel immunotherapies. Oncoimmunology. 2019;8(4): e1554969. https:\/\/doi.org\/10.1080\/2162402X.2018.1554969.","journal-title":"Oncoimmunology"},{"issue":"2","key":"3887_CR41","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1084\/jem.20140559","volume":"212","author":"T Voron","year":"2015","unstructured":"Voron T, Colussi O, Marcheteau E, Pernot S, Nizard M, Pointet AL, Latreche S, Bergaya S, Benhamouda N, Tanchot C, Stockmann C, Combe P, Berger A, Zinzindohoue F, Yagita H, Tartour E, Taieb J, Terme M. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med. 2015;212(2):139\u201348. https:\/\/doi.org\/10.1084\/jem.20140559.","journal-title":"J Exp Med"},{"issue":"2","key":"3887_CR42","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1158\/0008-5472.CAN-12-2325","volume":"73","author":"M Terme","year":"2013","unstructured":"Terme M, Pernot S, Marcheteau E, Sandoval F, Benhamouda N, Colussi O, Dubreuil O, Carpentier AF, Tartour E, Taieb J. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res. 2013;73(2):539\u201349. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-2325.","journal-title":"Cancer Res"},{"issue":"6","key":"3887_CR43","first-page":"2939","volume":"36","author":"M Tamiya","year":"2016","unstructured":"Tamiya M, Tamiya A, Yasue T, Nakao K, Omachi N, Shiroyama T, Tani E, Hamaguchi M, Morishita N, Suzuki H, Okamoto N, Okishio K, Kawaguchi T, Atagi S, Hirashima T. Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural Effusion. Anticancer Res. 2016;36(6):2939\u201344.","journal-title":"Anticancer Res"},{"issue":"3","key":"3887_CR44","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.lungcan.2008.12.007","volume":"65","author":"IL Hsu","year":"2009","unstructured":"Hsu IL, Su WC, Yan JJ, Chang JM, Lai WW. Angiogenetic biomarkers in non-small cell lung cancer with malignant pleural effusion: correlations with patient survival and pleural effusion control. Lung Cancer. 2009;65(3):371\u20136. https:\/\/doi.org\/10.1016\/j.lungcan.2008.12.007.","journal-title":"Lung Cancer"},{"issue":"2","key":"3887_CR45","first-page":"1129","volume":"35","author":"I Gkiozos","year":"2015","unstructured":"Gkiozos I, Tsagouli S, Charpidou A, Grapsa D, Kainis E, Gratziou C, Syrigos K. Levels of vascular endothelial growth factor in serum and pleural fluid are independent predictors of survival in advanced non-small cell lung cancer: results of a prospective study. Anticancer Res. 2015;35(2):1129\u201337.","journal-title":"Anticancer Res"},{"issue":"1","key":"3887_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40780-023-00314-w","volume":"10","author":"L Wang","year":"2024","unstructured":"Wang L, Fei Y, Qu H, Zhang H, Wang Y, Wu Z, Fan G. Five years of safety profile of bevacizumab: an analysis of real-world pharmacovigilance and randomized clinical trials. J Pharm Health Care Sci. 2024;10(1):1. https:\/\/doi.org\/10.1186\/s40780-023-00314-w.","journal-title":"J Pharm Health Care Sci"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03887-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-03887-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03887-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T08:52:55Z","timestamp":1757235175000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-025-03887-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3887"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-03887-y","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,14]]},"assertion":[{"value":"31 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"278"}}